Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phase 1b study of cyclophosphamide, pomalidomide, dexamethasone, and daratumumab (CPD-DARA) in relapsed/refractory multiple myeloma: Safety and efficacy in a heavily pretreated population

View Full Paper
Ask AI
Bookmark
Share

Authors

VMVitaliy MykytivMCMary R. CahillSBShikha Bakshi

Discussion

Loading...

Member takes

Overview

Phase 1b analysis demonstrates improved safety and efficacy in relapsed/refractory multiple myeloma, suggesting CPD-DARA may be a viable treatment option.

Key Points

  • CPD-DARA regimen achieved impressive median progression free survival of 15.0 months in heavily pretreated patients.
  • Severe treatment emergent adverse events occurred in 94% of participants, primarily neutropenia and infections.
  • Patient reported outcomes showed slight improvement from baseline to end of treatment despite high rates of toxicity.
  • These results support further investigation of CPD-DARA in larger clinical trials for treating relapsed/refractory multiple myeloma.

Cite This Study

Mykytiv et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da7fhttps://doi.org/10.1182/blood-2025-4031
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma – final results from a randomized investigator-initiated trial2025
  2. 2Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results2025
  3. 3Role of bortezomib maintenance therapy in the anti-CD38 antibody era: Interim analysis results of a randomized Phase III study for transplant-ineligible newly diagnosed multiple myeloma (JCOG1911/B-DASH Study)2025 · 1 citations
  4. 4Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd2025 · 2 citations
  5. 5Dara-RVD in newly diagnosed multiple myeloma: Real-world clinical practice2025